Question · Q4 2025
Peter Grom inquired about Hill's strong Q4 2025 volume performance despite a challenging category backdrop, asking where performance exceeded or fell short of expectations, and the outlook for Hill's continued outperformance.
Answer
Noel Wallace, Chairman, President, and CEO, reported Hill's strong quarter with 2% underlying volume growth (excluding private label), broad-based growth (except Dry softness), and improved two-year stack basis. He emphasized strong growth and market share gains in the therapeutic/prescription diet business, driven by science-based innovation across channels, despite pet adoption sluggishness. He also mentioned supply chain benefits from the Tonganoxie plant and increased brand advertising.
Ask follow-up questions
Fintool can predict
CL's earnings beat/miss a week before the call


